Preclinical development and selection of nanobody-based CAR-T cells targeting HER2-positive solid tumors
{{output}}
Chimeric antigen receptor (CAR)-T cell therapy revolutionized treatment of hematological malignancies, but translation to solid tumors remains difficult. Therefore, different avenues are explored to develop novel CAR-T cell products. Nanobodies have advantageo... ...
